Molecular Subgrouping and Prognostic Evaluation in Medulloblastoma

Medulloblastoma represents the most common malignant paediatric brain tumour, exhibiting marked molecular and clinical heterogeneity that underpins distinct therapeutic responses and outcomes. Over the past decade, consensus classification has defined four principal molecular subgroups—WNT, SHH, Group 3 and Group 4—each characterised by unique transcriptomic and epigenetic landscapes, signalling pathways and prognostic profiles. Recent refinements have unveiled further intra-subgroup diversity, with second-generation analyses delineating additional high-risk and low-risk clusters that enhance prognostic accuracy. Integration of genomics, DNA methylation and multiomic layers, including proteomics and glycomics, has facilitated the identification of subgroup-specific biomarkers and targetable alterations, paving the way for personalised risk-adapted therapies. Concurrent advances in immunogenomics have begun to chart the immunological landscape of each subgroup, uncovering neoantigens and tumour-associated antigens that may serve as substrates for novel immunotherapies. Metabolic profiling and radiomic signatures promise rapid and non-invasive subgroup assignment, potentially accelerating clinical decision-making. Collectively, these molecular subgrouping strategies and prognostic models are reshaping clinical protocols, enabling de-escalation of therapy in favourable-risk cohorts while guiding intensification in high-risk disease, and providing a robust framework for global collaborative trials aimed at improving survival and quality of life for affected children.

Research from Nature Portfolio

Recent studies have applied deep proteomic and glycomic profiling to refine functional subgroup definitions and identify targetable pathways. A comprehensive multiomic analysis of over 160 medulloblastoma specimens established six proteome subtypes that align with established transcription-based groups, revealing two main molecular programmes: transcription/translation and synaptic/immunological processes. This work demonstrated that aggressive Group 3 myc-driven tumours and favourable WNT tumours share overarching proteome clustering whilst exhibiting divergent expression of proteins linked to chemoresistance and glycan turnover. Integration with N-glycome data uncovered complex-bisecting glycan structures as a hallmark of high-risk tumours and suggested novel immunotherapy targets. Such high-resolution proteome–glycome maps offer a blueprint for pathway-directed interventions and underpin emerging studies of glycan-targeted immune modulation.

Molecular Subgrouping and Prognostic Evaluation in Medulloblastoma publication trend

The graph below shows the total number of articles in molecular subgrouping and prognostic evaluation in medulloblastoma across all publications each year (not limited to Nature Index journals).

Technical terms

Molecular subgroup: classification based on shared patterns of gene expression, DNA methylation and signalling pathway activation.

DNA methylation profiling: analysis of epigenetic modifications that guide subgroup assignment and prognostic modelling.

Proteome: complete complement of proteins expressed by a tumour, reflecting functional and regulatory programmes.

N-glycan: carbohydrate moieties attached to proteins that influence cell–cell interactions and immune recognition.

Neoantigen: novel peptide arising from tumour-specific mutations, capable of eliciting immune responses.

Tumour-associated antigen (TAA): proteins overexpressed or aberrantly expressed in cancer cells that can serve as immunotherapy targets.

Whole-chromosome aberration (WCA): gain or loss of entire chromosomes affecting tumour biology and prognosis.

Multiomic analysis: integrative investigation of multiple molecular layers, such as genome, transcriptome, proteome and glycome, to generate a comprehensive tumour profile.

References

1. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathologica (2012).
2. Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypes. Acta Neuropathologica (2019).
3. Multiomic profiling of medulloblastoma reveals subtype-specific targetable alterations at the proteome and N-glycan level. Nature Communications (2024).
4. Identification of tumor rejection antigens and the immunologic landscape of medulloblastoma. Genome Medicine (2024).
5. Metabolite profiles of medulloblastoma for rapid and non-invasive detection of molecular disease groups. EBioMedicine (2024).
6. Molecular characterisation defines clinically-actionable heterogeneity within Group 4 medulloblastoma and improves disease risk-stratification. Acta Neuropathologica (2023).
7. MR Imaging–Based Radiomic Signatures of Distinct Molecular Subgroups of Medulloblastoma. American Journal of Neuroradiology (2018).